Abstract
Risdiplam (Evrysdi (TM)) is an orally administered, survival motor neuron 2 (SMN2)-directed RNA splicing modifier being developed by Roche, PTC Therap......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
